Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

SimBioSys and General Inception Forge Strategic Alliance to Expedite Cancer Drug Development through Precision Oncology Innovation

NextEdge Admin

03 Apr 2024

3 min 16 sec

Cancer Drug Development,Precision Oncology

SimBioSys and General Inception have announced a strategic partnership aimed at revolutionizing oncology drug development through the integration of AI and biophysical modeling. This collaboration leverages SimBioSys’ PhenoScope platform, which analyzes vast amounts of multi-modal data to generate unique spatial biophysical insights crucial for cancer drug discovery.

PhenoScope’s capabilities stem from SimBioSys’ extensive data repository, encompassing over 12,000 individual cancer patient profiles and a virtual tumor bank with more than 20,000 spatially resolved tumors. This wealth of data, equivalent to over 100 terabytes, allows PhenoScope to predict personalized patient responses over time, including drug binding, metabolic response, and optimal dosing across various scenarios and delivery methods.

By deep phenotyping tumor biology and identifying biomarker sets with high predictive value, PhenoScope provides a versatile toolkit applicable throughout the drug development spectrum. From identifying novel biomarkers for new drugs to guiding patient selection and precision dosing, PhenoScope enhances the efficiency and effectiveness of oncology drug development.

General Inception, known for its venture studio model and portfolio of transformative companies, will integrate PhenoScope into all new oncology drug incubations. This integration is expected to streamline target identification, credentialing, and clinical positioning, thereby reducing time-to-clinic and improving efficacy through patient stratification and precision medicine approaches.

The partnership aligns with industry trends, such as the FDA’s Project Optimus, which aims to reform dose optimization paradigms in oncology drug development. With over 2,000 oncology products currently under development and significant growth in cancer medicine spending projected, the need for efficient and precise drug development processes is paramount.

Venkat Reddy, Chief Scientific Officer of General Inception, emphasized the potential of this collaboration to advance personalized cancer therapies by accelerating pipeline development. Tushar Pandey, CEO of SimBioSys, highlighted the commitment to introducing precision into drug development, underscoring the potential for reduced costs, increased efficacy, and minimized side effects.

The partnership between SimBioSys and General Inception represents a significant advancement in precision oncology, promising to deliver groundbreaking therapies to patients faster and more efficiently than ever before.